Deep Genomics

Two years ago, Deep Genomics was juggling about 40 different machine learning models to decode RNA biology. Now, they’ve revamped their approach with a single, powerful AI system known as BigRNA. This foundation model is capable of predicting how genes behave in different tissues, how they’re spliced, and how they interact with other cellular components…

Deep Genomics, a Toronto-based techbio company founded in 2014, recently opened a new office and lab in Cambridge, Massachusetts, an expansion of its Toronto office, and several leadership hires. The company, which has more than 100 employees with a background in areas spanning AI, automation, molecular biology, clinical development and software engineering, aims to develop…

The cell and gene therapy sector is poised to deliver a wave of new therapies with the potential to cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023. While manufacturing and regulatory challenges remain,…

Cell and gene therapies promise to enable broad changes in the healthcare system over the next decade, prompting a growing number of cell and gene therapy companies to join the space. Consider that a cell therapy technique could eliminate the need for immunosuppressive drugs for some organ transplant patients. Cell and gene therapy companies also…

The healthcare investment firm OrbiMed (New York City) has added two members to its team, including Dr. Tal Zaks, the former chief medical officer (CMO) at Moderna. Zaks will be a venture partner at Orbimed. Also joining the firm is Dr. Sheila Gujrathi, who was formerly the CEO of Gossamer Bio, who will be a…